{Reference Type}: Journal Article
{Title}: Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges.
{Author}: Lu J;Huo W;Ma Y;Wang X;Yu J;
{Journal}: Cancer Lett
{Volume}: 600
{Issue}: 0
{Year}: 2024 Sep 28
{Factor}: 9.756
{DOI}: 10.1016/j.canlet.2024.217185
{Abstract}: Glioblastoma, a highly malignant intracranial tumor, has acquired slow progress in treatment. Previous clinical trials involving targeted therapy and immune checkpoint inhibitors have shown no significant benefits in treating glioblastoma. This ineffectiveness is largely due to the complex immunosuppressive environment of glioblastoma. Glioblastoma cells exhibit low immunogenicity and strong heterogeneity and the immune microenvironment is replete with inhibitory cytokines, numerous immunosuppressive cells, and insufficient effective T cells. Fortunately, recent Phase I clinical trials of CART therapy for glioblastoma have confirmed its safety, with a small subset of patients achieving survival benefits. However, CART therapy continues to face challenges, including blood-brain barrier obstruction, antigen loss, and an immunosuppressive tumor microenvironment (TME). This article provides a detailed examination of glioblastoma's immune microenvironment, both from intrinsic and extrinsic tumor cell factors, reviews current clinical and basic research on multi-targets CART treatment, and concludes by outlining the key challenges in using CART cells for glioblastoma therapy.